P335 Impact of cancer therapy on the course of Inflammatory Bowel Disease (ONCOEII study of GETECCU)
Abstract Background Cancer in inflammatory bowel disease (IBD) patients is increasing mainly due to the aging of patients. There are few data regarding the effect of different types of cancer treatments in IBD disease outcome. The aim of the study was to evaluate the impact of cancer treatments on t...
Saved in:
Published in | Journal of Crohn's and colitis Vol. 17; no. Supplement_1; pp. i472 - i473 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
30.01.2023
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background
Cancer in inflammatory bowel disease (IBD) patients is increasing mainly due to the aging of patients. There are few data regarding the effect of different types of cancer treatments in IBD disease outcome. The aim of the study was to evaluate the impact of cancer treatments on the course of IBD patients.
Methods
An observational, multicenter, retrospective cohort study was conducted. We identified IBD patients diagnosed for an extraintestinal malignancy and who received any of the following cancer treatment types: chemotherapy, hormonal therapy, targeted therapy or immunotherapy. Patients who simultaneously received more than one different type of cancer treatment were excluded. Primary outcome was to evaluate the risk of IBD relapse for each type of cancer treatment. IBD relapse was defined as the need for additional medication, hospitalization or surgery related to IBD. Secondary outcomes were to describe the IBD treatment modifications after cancer diagnosis and to identify predictive factors for IBD relapse. IBD relapse was defined as the need for additional medication, hospitalization or surgery related to IBD. Predictive factors for IBD relapse were identified using multivariate Cox proportional hazard analysis.
Results
A total of 180 patients from 26 centers were included. Median age at cancer diagnosis was 57.5 years (IQR 46.8-67), 52.2% were female and 51.1% had Crohn’s disease. 36.1% and 20.6% were receiving immunomodulators and biologic drugs at the moment of cancer diagnosis respectively. IBD was in remission in most of the patients (85%). The most frequent malignancies were breast, prostate and hematological (33.9%, 12.2% and 12.2% respectively). IBD treatment was discontinued in 40.6% of patients at cancer diagnosis (77.1% of patients receiving thiopurines and 79.2% of those receiving anti-TNF drugs). 33% of patients experienced IBD relapse after cancer treatment initiation, at a median time of 7.6 months. IBD relapse was treated more frequently with steroids, vedolizumab and anti-TNF (56%, 15.2% and 13.6% respectively). In multivariate Cox-regression analysis, older age (HR=0.98; 95% CI [0.96-0.99]) and chemotherapy (HR=0.57; 95% CI [0.34-0.96]) were associated with a lower risk of IBD relapse, and active IBD at baseline (HR=2.9; 95% CI [1.67-5.07] was associated with a higher risk. Kaplan-Meier survival curves for time to IBD relapse are shown in Figures 1 and 2.
Conclusion
One out of three patients experienced IBD relapse after cancer treatment initiation. IBD drugs were discontinued in almost half of the cohort, specially thiopurines and anti-TNF drugs. Older age and chemotherapy were associated with a lower risk of IBD relapse, and active IBD at baseline with a higher risk. |
---|---|
AbstractList | Abstract
Background
Cancer in inflammatory bowel disease (IBD) patients is increasing mainly due to the aging of patients. There are few data regarding the effect of different types of cancer treatments in IBD disease outcome. The aim of the study was to evaluate the impact of cancer treatments on the course of IBD patients.
Methods
An observational, multicenter, retrospective cohort study was conducted. We identified IBD patients diagnosed for an extraintestinal malignancy and who received any of the following cancer treatment types: chemotherapy, hormonal therapy, targeted therapy or immunotherapy. Patients who simultaneously received more than one different type of cancer treatment were excluded. Primary outcome was to evaluate the risk of IBD relapse for each type of cancer treatment. IBD relapse was defined as the need for additional medication, hospitalization or surgery related to IBD. Secondary outcomes were to describe the IBD treatment modifications after cancer diagnosis and to identify predictive factors for IBD relapse. IBD relapse was defined as the need for additional medication, hospitalization or surgery related to IBD. Predictive factors for IBD relapse were identified using multivariate Cox proportional hazard analysis.
Results
A total of 180 patients from 26 centers were included. Median age at cancer diagnosis was 57.5 years (IQR 46.8-67), 52.2% were female and 51.1% had Crohn’s disease. 36.1% and 20.6% were receiving immunomodulators and biologic drugs at the moment of cancer diagnosis respectively. IBD was in remission in most of the patients (85%). The most frequent malignancies were breast, prostate and hematological (33.9%, 12.2% and 12.2% respectively). IBD treatment was discontinued in 40.6% of patients at cancer diagnosis (77.1% of patients receiving thiopurines and 79.2% of those receiving anti-TNF drugs). 33% of patients experienced IBD relapse after cancer treatment initiation, at a median time of 7.6 months. IBD relapse was treated more frequently with steroids, vedolizumab and anti-TNF (56%, 15.2% and 13.6% respectively). In multivariate Cox-regression analysis, older age (HR=0.98; 95% CI [0.96-0.99]) and chemotherapy (HR=0.57; 95% CI [0.34-0.96]) were associated with a lower risk of IBD relapse, and active IBD at baseline (HR=2.9; 95% CI [1.67-5.07] was associated with a higher risk. Kaplan-Meier survival curves for time to IBD relapse are shown in Figures 1 and 2.
Conclusion
One out of three patients experienced IBD relapse after cancer treatment initiation. IBD drugs were discontinued in almost half of the cohort, specially thiopurines and anti-TNF drugs. Older age and chemotherapy were associated with a lower risk of IBD relapse, and active IBD at baseline with a higher risk. |
Author | López-Cauce, B Dueñas Sadornil, C Lastiri González, E Pérez Galindo, P Capilla, M Barreiro-de Acosta, M Calviño-Suárez, C García, M J Melcarne, L Laredo de la Torre, V Vicuña, M Ponferrada, Á Gisbert, J P González-Vivo, M Castro, B Diz-Lois, M T Pérez Martínez, I Benítez, J M Sánchez-Azofra, M Tejido Sandoval, C Mañosa, M Ramírez de la Piscina, P Mesonero, F Bertoletti, F Rubín de Célix, C Ramírez Castro, C Castaño García, A Bernal, L Carpio, D Cousillas, A García-Morales, N Sánchez-Delgado, L |
Author_xml | – sequence: 1 givenname: P surname: Pérez Galindo fullname: Pérez Galindo, P – sequence: 2 givenname: J M surname: Benítez fullname: Benítez, J M – sequence: 3 givenname: C surname: Rubín de Célix fullname: Rubín de Célix, C – sequence: 4 givenname: F surname: Mesonero fullname: Mesonero, F – sequence: 5 givenname: A surname: Castaño García fullname: Castaño García, A – sequence: 6 givenname: M J surname: García fullname: García, M J – sequence: 7 givenname: M surname: Vicuña fullname: Vicuña, M – sequence: 8 givenname: L surname: Bernal fullname: Bernal, L – sequence: 9 givenname: F surname: Bertoletti fullname: Bertoletti, F – sequence: 10 givenname: C surname: Ramírez Castro fullname: Ramírez Castro, C – sequence: 11 givenname: M surname: Sánchez-Azofra fullname: Sánchez-Azofra, M – sequence: 12 givenname: L surname: Sánchez-Delgado fullname: Sánchez-Delgado, L – sequence: 13 givenname: Á surname: Ponferrada fullname: Ponferrada, Á – sequence: 14 givenname: C surname: Tejido Sandoval fullname: Tejido Sandoval, C – sequence: 15 givenname: M surname: Capilla fullname: Capilla, M – sequence: 16 givenname: V surname: Laredo de la Torre fullname: Laredo de la Torre, V – sequence: 17 givenname: M T surname: Diz-Lois fullname: Diz-Lois, M T – sequence: 18 givenname: C surname: Dueñas Sadornil fullname: Dueñas Sadornil, C – sequence: 19 givenname: N surname: García-Morales fullname: García-Morales, N – sequence: 20 givenname: M surname: González-Vivo fullname: González-Vivo, M – sequence: 21 givenname: B surname: López-Cauce fullname: López-Cauce, B – sequence: 22 givenname: L surname: Melcarne fullname: Melcarne, L – sequence: 23 givenname: C surname: Calviño-Suárez fullname: Calviño-Suárez, C – sequence: 24 givenname: E surname: Lastiri González fullname: Lastiri González, E – sequence: 25 givenname: P surname: Ramírez de la Piscina fullname: Ramírez de la Piscina, P – sequence: 26 givenname: J P surname: Gisbert fullname: Gisbert, J P – sequence: 27 givenname: I surname: Pérez Martínez fullname: Pérez Martínez, I – sequence: 28 givenname: B surname: Castro fullname: Castro, B – sequence: 29 givenname: A surname: Cousillas fullname: Cousillas, A – sequence: 30 givenname: M surname: Mañosa fullname: Mañosa, M – sequence: 31 givenname: D surname: Carpio fullname: Carpio, D – sequence: 32 givenname: M surname: Barreiro-de Acosta fullname: Barreiro-de Acosta, M |
BookMark | eNot0FFLwzAQB_AgE9ymH0HIoz50S5omTR61Vi0M58N8DrdbiitrM5IO6bd31T3dH_7HcfxmZNL5zhFyz9mCMyOWDtEnDeKyaQC5YQuWKXlFplznKsmy3Ez-skiMydQNmcXYMCaNzPWU7D6FkLRqj4A99TVF6NAF2n-7AMeB-m6MFP0pRDf2VVcfoG2h92Ggz_7HHejLPjo4tw_rj2JdVhWN_Wk3jMtv5aYsiq_HW3JdwyG6u8uck81ruSnek9X6rSqeVgkaIRPU56-2aab51qQi57CDGmqmTZ4DCgdaO5XJlInUKbN1OpVCoHSMswxQKSXmRP6fxeBjDK62x7BvIQyWMztK2VHKnqXsRcqOUuIX3-Vfcw |
ContentType | Journal Article |
CorporateAuthor | GETECCU |
CorporateAuthor_xml | – name: GETECCU |
DBID | AAYXX CITATION |
DOI | 10.1093/ecco-jcc/jjac190.0465 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1876-4479 |
EndPage | i473 |
ExternalDocumentID | 10_1093_ecco_jcc_jjac190_0465 |
GroupedDBID | --- --K 0R~ 1B1 1~. 1~5 4.4 48X 4G. 5GY 5WD 7-5 71M AABZA AACZT AAMVS AAOGV AAPQZ AAPXW AARHZ AASNB AAUAY AAVAP AAYXX ABBQC ABDBF ABEUO ABIXL ABJNI ABNHQ ABPTD ABQLI ABQNK ABWST ABXVV ACGFS ACUFI ACYHN ADBBV ADGZP ADHKW ADHZD ADIPN ADJQC ADQBN ADRIX ADRTK ADVEK ADYVW AEGPL AEJOX AEKER AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGQXC AGSYK AGUTN AGYEJ AJEEA AJRQY ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT ATGXG AVWKF AXUDD BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM CDBKE CITATION CS3 DAKXR DILTD DU5 EBS ENERS EO8 EO9 EP2 EP3 F5P FDB FECEO FLUFQ FNPLU FOEOM FOTVD FQBLK GAUVT GBLVA GJXCC H13 HAR IHE J1W J21 KOP KSI KSN MHKGH MO0 N9A NOMLY NOYVH O-L OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OPAEJ OVD OWPYF OZT P-8 P-9 P2P PAFKI PC. PEELM Q5Y RIG ROX RPZ RUSNO RXO SDF SDG SEL SES TEORI TJX YAYTL YKOAZ YXANX |
ID | FETCH-LOGICAL-c935-c8005b2481b92371adafaf08977ac3ea88e6452032e69be82533c5e0104ac6663 |
ISSN | 1873-9946 |
IngestDate | Fri Aug 23 09:42:22 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c935-c8005b2481b92371adafaf08977ac3ea88e6452032e69be82533c5e0104ac6663 |
OpenAccessLink | https://academic.oup.com/ecco-jcc/article-pdf/17/Supplement_1/i472/48952905/jjac190.0465.pdf |
ParticipantIDs | crossref_primary_10_1093_ecco_jcc_jjac190_0465 |
PublicationCentury | 2000 |
PublicationDate | 2023-01-30 |
PublicationDateYYYYMMDD | 2023-01-30 |
PublicationDate_xml | – month: 01 year: 2023 text: 2023-01-30 day: 30 |
PublicationDecade | 2020 |
PublicationTitle | Journal of Crohn's and colitis |
PublicationYear | 2023 |
SSID | ssj0059578 |
Score | 2.3550115 |
Snippet | Abstract
Background
Cancer in inflammatory bowel disease (IBD) patients is increasing mainly due to the aging of patients. There are few data regarding the... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | i472 |
Title | P335 Impact of cancer therapy on the course of Inflammatory Bowel Disease (ONCOEII study of GETECCU) |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEF5cB0ovoU_6Zg89tJh1ZO3qscdYcV7gEooDuYnVakUTWqs4Ni35kf1NndGsbLkNpelFllfSIHs-Zuc9jL1T2mnYVwMRgAQWKlWFKBKlhHWwYKq4KptwwfRjfHyuTi-ii17vZydrabUshvbm1rqS_-EqrAFfsUr2DpxdE4UFOAf-whE4DMd_4vGZlBH29_V1jhY52CQNYqMAHwYY2BrzNKhkpAL-f6W4-rj-7lDiNfGZpukomPeTkxNqOIu3H01mkyw7b30Ff2qw2aL-TBNZqDgOM-nWKvoZheAX7mZwBLr-vKy3qsnGIO7whoMlubBPN27ZT6uCLmGe7iAjOl8uf2z5dKfuGlss1ZvkZO-6CDFxq43CkLRNEym09j5I167FQimaMLMW0UkHis2408Z3mo86ovdS0Qwgv43DV3nrFkHtswC5tbiyFneLK2NBLRoGiqZWbDfl_m2zXKcwUvBe5kgoB0K5J5MjmXtsJ0x0lPTZzv74YHzY6gYRrDXFme0Pb2vKtNxr32iv-z4dbamj9swesl3Pbb5P4HvEem7-mN2f-oyMJ6xEDHLCIK8rThjkHoO8nuMpJwzi9S4GeYNB7jHI33sE8gaBeLNH4IenbHY4mWXHwk_uEFbLSFiwQqIiVGASgf2QjExpKlMFKdgaxkpn0tRhPD2QoYt14dIQbA4bOXQNGAv2tHzG-nMA0XPGI4OV3bGzpbYqdKbAeQ_RKE5LDZ9V-YIN2z8o_0b9WfK_sublXR94xR5ssPua9ZeLlXsDiuiyeOu5-wvJU4OS |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=P335+Impact+of+cancer+therapy+on+the+course+of+Inflammatory+Bowel+Disease+%28ONCOEII+study+of+GETECCU%29&rft.jtitle=Journal+of+Crohn%27s+and+colitis&rft.au=P%C3%A9rez+Galindo%2C+P&rft.au=Ben%C3%ADtez%2C+J+M&rft.au=Rub%C3%ADn+de+C%C3%A9lix%2C+C&rft.au=Mesonero%2C+F&rft.date=2023-01-30&rft.issn=1873-9946&rft.eissn=1876-4479&rft.volume=17&rft.issue=Supplement_1&rft.spage=i472&rft.epage=i473&rft_id=info:doi/10.1093%2Fecco-jcc%2Fjjac190.0465&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_ecco_jcc_jjac190_0465 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1873-9946&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1873-9946&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1873-9946&client=summon |